Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | ME2 | P23368 | 2/20 | 0.40 |
| ▸ | ME1 | P48163 | 2/20 | 0.40 |
| ▸ | ME3 | Q16798 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8060409 | 0.82 | KCNN4 (0.43) | HTTHDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL3975166 | 0.81 | POLB (0.38) | CYP2C19HIF1ATAAR1PTPN1MAPT | |
| SCHEMBL7207085 | 0.79 | CYP2C19 (0.42) | CYP2C19HIF1ATAAR1PTPN1ME2 | |
| SCHEMBL10563207 | 0.79 | CYP2C19 (0.48) | CYP2C19HIF1ATAAR1PTPN1ME2 | |
| SCHEMBL873147 | 0.78 | CYP2C19 (0.52) | CYP2C19HIF1ATAAR1ME2ME1 | |
| SCHEMBL6237816 | 0.78 | HDAC6 (0.36) | CYP2C19HIF1AMAPTPOLBHDAC3 | |
| SCHEMBL9229179 | 0.76 | ACP3 (0.47) | ALDH1A1 | |
| SCHEMBL16819652 | 0.76 | CYP1A2 (0.40) | CYP2C19HIF1ATAAR1PTPN1ALDH1A1 | |
| SCHEMBL8345266 | 0.76 | RIPK1 (0.34) | CYP2C19HIF1AMAPTKMT2ACYP1A2 | |
| SCHEMBL57411 | 0.75 | CYP2C19 (0.69) | CYP2C19HIF1ATAAR1ME2ME1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1721894-A1 | Process for the synthesis of prostaglandin derivatives | Technopharma S.A. (IT) | 2006-11-15 | — | — | EP | claimed |
| US-20220169600-A1 | METHOD FOR PRODUCING PKROSTAGLANDIN | KYOWA PHARMA CHEMICAL CO., LTD. (JP) | 2022-06-02 | — | — | US | disclosed |
| EP-3950672-A1 | METHOD FOR PRODUCING PKROSTAGLANDIN | Kyowa Pharma Chemical Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020195437-A1 | METHOD FOR PRODUCING PKROSTAGLANDIN | 協和ファーマケミカル株式会社 | 2020-10-01 | — | — | WO | disclosed |
| EP-1225168-B2 | Prostaglandin-F-2 alpha derivative for the treatment of glaucoma or ocular hypertension | PFIZER HEALTH AB (SE) | 2015-01-21 | — | — | EP | disclosed |
| US-20120016136-A1 | PROCESS FOR THE PREPARATION OF PROSTAGLANDIN DERIVATIVES | SIFAVITOR S.R.L. (IT) | 2012-01-19 | — | — | US | disclosed |
| EP-2401252-A1 | PROCESS FOR THE PREPARATION OF PROSTAGLANDIN DERIVATIVES | Sifavitor S.r.l. (IT) | 2012-01-04 | — | — | EP | disclosed |
| EP-2311820-A1 | Process for the purification of latanoprost by HPLC | Resolution Chemicals Limited (GB) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010097672-A1 | PROCESS FOR THE PREPARATION OF PROSTAGLANDIN DERIVATIVES | SIFAVITOR S.R.L. (IT) | 2010-09-02 | — | — | WO | disclosed |
| US-20090259066-A1 | Method for preparing prostaglandin F analogue | EVERLIGHT USA, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-RE29926-E | 2-Decarboxy-2-hydroxy-methyl-16-fluoro-PGE1 compounds | THE UPJOHN COMPANY (US) | 1979-03-06 | — | — | US | disclosed |
| US-4104474-A | PROSTAGLANDINS, HYPOTENSIVE, OXYTOCICS, ANTIFERTILITY, ANTISECRETORY | THE UPJOHN COMPANY (US) | 1978-08-01 | — | — | US | disclosed |
| US-4099015-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-07-04 | — | — | US | disclosed |
| US-4058564-A | PROSTAGLANDINS; HYPOTENSIVE, LABOR INDUCERS, ANTISECRETORY | THE UPJOHN COMPANY (US) | 1977-11-15 | — | — | US | disclosed |
| US-4055602-A | PROSTAGLANDIN | THE UPJOHN COMPANY (US) | 1977-10-25 | — | — | US | disclosed |
| US-4029681-A | 13,14-Didehydro-PG analogs | THE UPJOHN COMPANY (US) | 1977-06-14 | — | — | US | disclosed |
| US-4028419-A | PROSTAGLANDINS | THE UPJOIN COMPANY (US) | 1977-06-07 | — | — | US | disclosed |
| US-4026909-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1977-05-31 | — | — | US | disclosed |
| US-4018803-A | 13,14-Didehydro-PG3 compounds | THE UPJOHN COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
| US-4013695-A | PROSTAGLANDINS, HYPOTENSIVES, OXYTOCICS, ANTISECRETORY AND ANTIULCER AGENTS, REPRODUCTION CONTROL | THE UPJOHN COMPANY (US) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090259066-A1 | Method for preparing prostaglandin F analogue | PTGER1, PTGIR, PTGIS | CYP2C19 77/4885HIF1A 830/4885TAAR1 658/4885 |
| US-20220169600-A1 | METHOD FOR PRODUCING PKROSTAGLANDIN | PTGS1, PTGER1, RACK1 | CYP2C19 897/4885HIF1A 224/4885TAAR1 1345/4885 |
| US-20120016136-A1 | PROCESS FOR THE PREPARATION OF PROSTAGLANDIN DERIVATIVES | PTGIS, PTGES, PTGIR | CYP2C19 97/4885HIF1A 1799/4885TAAR1 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.